NCT05023070View on ClinicalTrials.gov

Investigation of the Pharmacokinetic Profile of CBD - Phase 1 ANANDA

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 22, 2021

Primary Completion Date

February 16, 2023

Study Completion Date

February 16, 2023

Conditions
Healthy
Interventions
DRUG

Cannabidiol

Cannabidiol 200 mg

DRUG

Cannabidiol

Cannabidiol 400 mg

DRUG

Cannabidiol

Epidiolex 400 mg

DRUG

Cannabidiol

Cannabidiol 400 mg

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT05023070 - Investigation of the Pharmacokinetic Profile of CBD - Phase 1 ANANDA | Biotech Hunter | Biotech Hunter